(NASDAQ: LBRX) Lb Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.51%.
Lb Pharmaceuticals's earnings in 2025 is N/A.On average, 4 Wall Street analysts forecast LBRX's earnings for 2025 to be -$63,146,590, with the lowest LBRX earnings forecast at -$68,352,526, and the highest LBRX earnings forecast at -$56,772,837. On average, 4 Wall Street analysts forecast LBRX's earnings for 2026 to be -$88,364,222, with the lowest LBRX earnings forecast at -$103,809,168, and the highest LBRX earnings forecast at -$70,702,232.
In 2027, LBRX is forecast to generate -$74,525,278 in earnings, with the lowest earnings forecast at -$86,868,772 and the highest earnings forecast at -$60,360,711.